EGRX - イ―グル・ファ―マシュ―ティカルズ （Eagle Pharmaceuticals Inc.） イ―グル・ファ―マシュ―ティカルズEGRXのチャート
EGRXの企業情報
| symbol | EGRx |
|---|---|
| 会社名 | Eagle Pharmaceuticals Inc. （イ―グル・ファ―マシュ―ティカルズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 イーグル・ファーマスーティカルス（Eagle Pharmaceuticals Inc.）は専門の製薬会社。同社は救命救急診療と腫瘍分野での注射用製品の開発と製品化を行う。同社の製品ポートフォリオはアルガトロバン、Ryanodex、ドセタキセル注射剤、非アルコール製剤、ベンデカを含む。同社の上級候補製品はベンダムスチン抵抗値温度検出器（RTD）EP-3101、熱中症用のダントロレンナトリウム（EHS）EP-4104、薬物誘発性高体温用のダントロレンナトリウムEGL-4104-C-1702、ペメトレキセドEP-5101、フルベストラントEGL-5385-C-1701。同社の製品ポートフォリオはがん治療、救急医療、希少疾病に注目する。ベンダムスチンは、リツキシマブまたはリツキシマブ含有レジメンによる治療の6カ月または6カ月以内に進行した慢性リンパ球性白血病（CLL）および無痛性B細胞非ホジキンリンパ腫（NHL）に使用が認可されるアルキル化剤である。 イ―グル・ファ―マシュ―ティカルズは米国の特殊医薬品会社。米国食品医薬品局(FDA)の505(b)(2)による規制手順を活用して、主に救命救急及び腫瘍学分野の注射製剤の開発・商業化に重点を置く。先進的な製品には、悪性高熱症のための懸濁注射剤「Ryanodex」がある。本社はニュ―ジャ―ジ―州。 Eagle Pharmaceuticals Inc. is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in meaningful improvements in patients' lives. Eagle's commercialized products include RYANODEX®, BENDEKA®, BELRAPZO®, and its oncology and CNS/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. |
| 本社所在地 | 50 Tice Boulevard Suite 315 Woodcliff Lake NJ 07677 USA |
| 代表者氏名 | Michael Graves マイケル・グレイブス |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 201-326-5300 |
| 設立年月日 | 39083 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2014年 |
| 従業員数 | 108人 |
| url | www.eagleus.com |
| nasdaq_url | https://www.nasdaq.com/symbol/egrx |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） 59.09800 |
| 終値（lastsale） | 63.42 |
| 時価総額（marketcap） | 954846700.08 |
| 時価総額 | 時価総額（百万ドル） 948.07150 |
| 売上高 | 売上高（百万ドル） 215.72800 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 894.54250 |
| 当期純利益 | 当期純利益（百万ドル） 33.19100 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Eagle Pharmaceuticals Inc revenues decreased 17% to $105.9M. Net income decreased 81% to $5.3M. Revenues reflect License and other income decrease from $25M to $0K Royalty revenue decrease of 3% to $72M. Net income also reflects Research and development - Balancing val increase from $10.1M to $27.5M (expense) IE on Capital Financing Gross increase from $67K to $1.4M (expense). |
EGRXのテクニカル分析
EGRXのニュース
Eagle Pharmaceuticals Granted Unique J-Code for Byfavo¹ (remimazolam for injection) from CMS 2023/05/01 10:50:00 Wallstreet:Online
-- Byfavo1 is indicated for the induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less WOODCLIFF LAKE, N.J., May 01, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the Centers for Medicare & Medicaid Services (“CMS”) has established a unique, product-specific billing
Eagle Pharmaceuticals to Host First Quarter 2023 Financial Results on May 9, 2023 2023/04/27 20:30:00 GlobeNewswire
WOODCLIFF LAKE, N.J., April 27, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its first quarter 2023 financial results on Tuesday, May 9, 2023, before the market opens.
Eagle Pharma reaches settlement agreement with Dr. Reddy’s Lab 2023/04/05 16:12:39 Seeking Alpha
Eagle Pharmaceuticals (EGRX) said it had reached a settlement agreement with Dr
Eagle Pharmaceuticals reaches settlement with Dr. Reddys Laboratories on BENDEKA 2023/04/05 11:02:02 Investing.com
https://www.investing.com/news/assorted/eagle-pharmaceuticals-reaches-settlement-with-dr-reddys-laboratories-on-bendeka-432SI-3049393
Eagle Pharmaceuticals Reaches Settlement Agreement with Dr. Reddy’s Laboratories Inc. and Dr. Reddy’s Laboratories Ltd. Related to BENDEKA (bendamustine hydrochloride) 2023/04/05 10:50:00 Wallstreet:Online
WOODCLIFF LAKE, N.J., April 05, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that it has reached a settlement agreement with Dr. Reddy’s Laboratories, Ltd. and Dr. Reddy’s Laboratories, Inc. (collectively, “Dr. Reddy’s”). Eagle had asserted its Orange Book-listed patents against Dr. Reddy’s related to its new drug
Eagle Pharmaceuticals to Host Fourth Quarter and Full Year 2022 Financial Results on March 13, 2023 2023/03/03 11:50:00 GlobeNewswire
WOODCLIFF LAKE, N.J., March 03, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its fourth quarter and full year 2022 financial results on Monday, March 13, 2023, before the market opens. Scott Tarriff, President and Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will host a conference call to discuss the results as follows:
Eagle Pharmaceuticals: Upside Could Be Lying Ahead Very Nicely 2023/01/25 11:01:24 Seeking Alpha
Eagle Pharmaceuticals is an interesting opportunity to benefit from volatility in stock markets. Click here to find out why EGRX stock is a Hold.
EGRX stock slips as 2023 guidance meets consensus (NASDAQ:EGRX) 2023/01/10 20:13:01 Seeking Alpha
Eagle Pharma (EGRX) announced its preliminary guidance for 2023 on Tuesday, indicating $4.20-$4.53 of adjusted non-GAAP earnings per share in line with consensus. Read the full story here.
Eagle Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference 2022/12/21 21:30:00 GlobeNewswire
WOODCLIFF LAKE, N.J., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present at the 41 st Annual J.P. Morgan Healthcare Conference as follows:
Eagle Pharmaceuticals Receives FDA Approval for Additional Indication for PEMFEXY in Combination with Pembrolizumab and Platinum Chemotherapy 2022/12/19 11:50:00 Wallstreet:Online
-- Additional indication is for the initial treatment of patients with metastatic, non-squamous, non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations -- -- Represents the fifth indication for PEMFEXY, a ready-to-use liquid with a unique J-code approved to treat non-squamous non-small cell lung cancer and mesothelioma -- WOODCLIFF LAKE, N.J., Dec. 19, 2022 (GLOBE NEWSWIRE)
Eagle, Enalare''s ENA-001 for sleep disorder in newborns get FDA orphan drug status 2022/10/03 11:24:01 Seeking Alpha
The U.S. Food and Drug Administration (FDA) granted orphan drug designation to Eagle Pharmaceuticals (EGRX) and Enalare Therapeutics'' ENA-001 to treat Apnea of Prematurity (AoP).AoP…
Enalare Secures BARDA Award Of $50M For ENA-001 In Drug Overdose 2022/09/27 14:59:59 Benzinga
Eagle Pharmaceuticals Inc (NASDAQ: EGRX ) announced that Enalare Therapeutics Inc secured a contract for up to $50.3 million from the Biomedical Advanced Research and Development Authority (BARDA). In partnership with BARDA, ENA-001 is being developed in an intramuscular (IM) formulation for potential use in patients experiencing community drug overdose and as a potential … Full story available on Benzinga.com
Eagle Pharmaceuticals Inc. (NASDAQ: EGRX) Is An Exciting Stock To Watch. 2022/09/17 13:30:00 Stocks Register
Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) shares, rose in value on Friday, 09/16/22, with the stock price down by -3.95% to the previous day’s close as strong demand from buyers drove the stock to $28.93. Actively observing the price movement in the last trading, the stock closed the session at $30.12, falling within a range of $27.91 … Eagle Pharmaceuticals Inc. (NASDAQ: EGRX) Is An Exciting Stock To Watch. Read More »
Eagle Pharmaceuticals to Present at the Morgan Stanley 20th Annual Global Healthcare Conference 2022/08/30 20:05:00 GlobeNewswire
WOODCLIFF LAKE, N.J., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, President and Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present at the Morgan Stanley 20 th Annual Global Healthcare Conference as follows:
Endo loses appeal challenging generic version of best-seller Vasostrict 2022/08/18 19:01:30 Reuters
Endo International''s Par Pharmaceutical Inc on Wednesday failed to persuade a U.S. appeals court to revive its lawsuit seeking to block Eagle Pharmaceuticals Inc from selling a generic version of Par''s best-selling blood-pressure drug Vasostrict.